Alphamab Oncology

Pharmaceutical ManufacturingChina11-50 Employees

Alphamab Oncology is a biopharmaceutical company based in Suzhou, Jiangsu, China, focused on oncology therapeutics. It pursues a pipeline spanning antibody-drug conjugates, bispecific antibodies, and single-domain antibodies, supported by proprietary platforms and formulations. Envafolimab (KN035) is market approved as the first subcutaneously injected PD-(L)1 inhibitor, and KN026 has had its NDA accepted by the NMPA for second-line or later HER2-positive gastric cancer; the company has formed partnerships with CSPC, ArriVent, and Glenmark to support development and access to technology.

Alphamab has multiple bispecific ADC candidates in clinical stages, and next-generation ADC pipelines such as dual-payload approaches are under development. Recent regulatory activity includes the NMPA accepting IND for JSKN021, a dual-payload EGFR/HER3 bispecific ADC, and the company presenting Phase 1 data for JSKN016 at ASCO 2026. Additionally, the company was recognized as a 2024 Top 100 Chinese Pharmaceutical Innovative Enterprise at the China Healthcare Summit.

Sign up for free to view info

Email Format Employee directory